GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: This is one of the more potent compounds claimed in patent WO2023245150A1 (Prelude Therapeutics) as lysine acetyltransferase 6A (KAT6A) degraders [1]. It is a PROTAC heterobifunctional molecule with a thalidomide-based cereblon ubiquitin ligase binding moiety linked to a selective KAT6A binding ligand. It promotes formation of a ternary complex that directs KAT6A protein for proteosomal degradation. This mechanism is proposed as an alternative to direct enzyme inhibition.
                                    
                                 | 
 | |||||||||||||||||||||||||||||||||||
| Bioactivity Comments | 
| DC50 for KAT6A is <10 nM, with a Dmax >75% [1]. | 
| Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
| 
 | ||||||||||||||||||||||||||||||||||